Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?-Reference-Cited by-同舟云学术

Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

Published:2018-06-03 Issue:8 Volume:84 Page:1635-1638
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Eşkazan Ahmet Emre¹^ORCID

Affiliation:

1. Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine; Istanbul University; Istanbul Turkey

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13637/fullpdf

Reference34 articles.

1. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

2. IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017

3. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol,2016

4. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials;Sasaki;Lancet Haematol,2015

5. Deep molecular responses for treatment-free remission in chronic myeloid leukemia;Dulucq;Cancer Med,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?;Expert Review of Hematology;2020-09-08

2. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic;British Journal of Clinical Pharmacology;2020-05-20

3. Novel therapeutic approaches in chronic myeloid leukemia;Leukemia Research;2020-04

4. Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia;Future Oncology;2020-01

5. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest?;British Journal of Clinical Pharmacology;2019-08-22